Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection
via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a
double-blind, active-controlled manner. The study is also to examine the safety of compound
Edaravone Injection for the AIS patients.